Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

New innovations targeting dry eye disease (DED) are in the pipeline to enable us to tailor our treatments to the specific underlying causes of DED.

  • By

  • SHANE R. KANNARR, OD

  • Christoper J. Jacquinot, OD

  • Ryan A. Cedeno, OD

  • July 1, 2025

  • 1 min

Share

Objective:

To discuss new treatment options in development for dry eye disease (DED).

Approach:
    Key Findings:
    • Reproxalap may reduce inflammation in DED and allergy patients.
    • AZR-MD-001 could enhance meibum quality in meibomian gland dysfunction.
    • OCS-02 targets ocular inflammation related to DED.
    • Softacort may alleviate symptoms when used with proper lid care.
    Interpretation:

    These emerging therapies represent a tailored approach to treating the underlying causes of dry eye disease.

    Conclusion:

    The development of these pharmaceuticals indicates progress in addressing the diverse mechanisms of dry eye disease.

Original Source(s)

Leading Off: Pharmaceuticals in the Dry Eye Disease Pipeline

  • by SHANE R. KANNARR, OD, Christoper J. Jacquinot, OD, Ryan A. Cedeno, OD

  • July 1, 2025

Related Content

Quality Assessment of Dry Eye Educational Videos on Xiaohongshu and Differences by Uploader Type

Scleral Lens Evolution

This article will examine the indications, clinical evidence, and practical considerations for managing severe ocular surface disease and inflammatory dry eye using scleral lenses, and offer guidance to practitioners who seek to expand their therapeutic options.

The Hormonal Link to Ocular Disease in Women

Neda Gioia, OD, CNS, FMCP, FOWNS, reviewed how levels of individual hormones and the balance between them help regulate tear production, inflammation, wound healing, lipid secretion, intraocular pressure (IOP), and neuroprotection, and therefore can result in a higher burden of dry eye, glaucoma, or retinal disease in women.